|
Accueil > Actualité
Pfizer: favourable data for a Covid-19 vaccine
(CercleFinance.com) - Pfizer and BioNTech announced on Thursday evening favourable Phase I safety and immunogenicity data for their investigational vaccine BNT162b2 against SARS-CoV-2, the virus responsible for Covid-19, which has progressed into Phase II/III evaluation.
Assuming clinical success, they plan to seek regulatory review of BNT162b2 as early as October 2020 and, if approved, to supply up to 100 million doses worldwide by the end of 2020 and approximately 1.3 billion doses by the end of 2021. Copyright (c) 2020 CercleFinance.com. All rights reserved. |
19/04/2024 18:06
Alstoma conclu un accord avec Knorr-Bremse 19/04/2024 17:30 Danoneen hausse après deux analyses positives 19/04/2024 16:35 TotalEnergiespartenariat avec OK Petroleum aux USA 19/04/2024 16:29 BAE Systemsmodernise une usine de munitions 19/04/2024 16:15 Netflixle titre trébuche après une publication contrastée 19/04/2024 16:09 Bayersigne un contrat de fourniture d'énergie renouvelables Tous les articles sociétés |
